Canaccord Initiates Coverage of Ocugen, Inc. (OCGN) with a Buy Rating and a $12 Price Target

Ocugen, Inc. (NASDAQ:OCGN) is one of the 11 Best High Volume Penny Stocks to Buy Now. On March 17, 2026, Canaccord initiated coverage of Ocugen, Inc. (NASDAQ:OCGN) with a Buy rating and a $12 price target, citing the company’s three clinical-stage programs in retinal diseases and describing early data as “interesting.” Canaccord added that the upcoming Q3 data could serve as a “de-risking event” as those programs advance.

On March 11, 2026, Oppenheimer initiated coverage of OCGN with an Outperform rating and a $10 price target, viewing the company as an emerging gene therapy player in ocular disorders. Oppenheimer pointed to OCU400, currently in Phase 3 for retinitis pigmentosa, and said a potential 2027 approval could provide entry into a “sizable and poorly-met” rare disease market. Meanwhile, Lucid Capital analyst Elemer Piros raised the price target on OCGN to $22 from $15 and maintained a Buy rating following positive preliminary Phase 2 data for OCU410 in geographic atrophy.

Photo by Mohammad Shahhosseini on Unsplash

On March 4, 2026, OCGN reported Q4 EPS of (6c), in line with the (6c) consensus estimate. CEO Dr. Shankar Musunuri described 2025 as a “transformative year,” highlighting progress across its gene therapy programs alongside licensing and financing agreements that strengthened the company’s position. Musunuri added that Ocugen is approaching the first of three planned BLA filings as it advances its pipeline.

Ocugen, Inc. (NASDAQ:OCGN) develops gene and cell therapies, biologics, and vaccines focused on improving patient outcomes.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None.  Follow Insider Monkey on Google News.